Hanson Pharmaceutical Surges Over 5% After Earnings, Mid-Year Profit Rises 15.02% to HK$31.35 Billion

Hanson Pharmaceutical (03692) surged nearly 6% after earnings, with the stock price rising 5.24% to HK$39 per share, trading volume of HK$2.319 billion.

Hanson Pharmaceutical announced its mid-year results, achieving revenue of RMB74.34 billion, up 14.27% year-on-year; the parent company's attributable profit reached HK$31.35 billion, up 15.02% year-on-year; earnings per share were HK$0.53, and the company plans to distribute a mid-year dividend of HK$23.16 per share. The company has launched seven innovative drug products in China. In the first half of 2025, sales revenue from innovative drugs and collaborative products was approximately HK$61.45 billion, accounting for around 82.7% of total revenue.